AI assistant
Sending…
KALA BIO, Inc. — Director's Dealing 2022
Nov 1, 2022
35091_dirs_2022-11-01_2b30e442-2ac2-40af-8f6e-ffc083a7e6e1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2022-10-31
Reporting Person: Farid Marjan (N/A)
More from KALA BIO, Inc.
Interim / Quarterly Report
2026
May 15
Annual Report
2026
Apr 15
Regulatory Filings
2026
Mar 17
Regulatory Filings
2026
Mar 17
Capital/Financing Update
2026
Mar 4
Board/Management Information
2026
Feb 20
Major Shareholding Notification
2026
Feb 17
Capital/Financing Update
2026
Feb 9
Director's Dealing
2026
Feb 9
Director's Dealing
2026
Feb 9